Our Contributors

Tim Weinheimer's picture

Tim Weinheimer

Senior Vice President, Group Account Director, Ketchum, Washington, D.C.

Tim works with Ketchum brands to develop strategies to stay ahead by leveraging the latest innovations and thinking in digital marketing, technology and the web. Tim brings diverse marketing leadership experience having worked for some of the nation’s top advertising agencies including The Richards Group, Ogilvy & Mather, McCann-Erickson, and DDB Needham. Having cut his teeth in marketing during the deregulation of telecommunications working on the Verizon (formerly GTE) and AT&T Wireless accounts, he has become central to leading agencies’ digital transformation and interactive work across various industries including healthcare, telecommunications, financial services and retail. His strategic thinking and non-stop focus on the clients’ business have dramatically built awareness and sales for top brands including GlaxoSmithKline, Coopervision, Clorox, AT&T, Moen, MetroPCS and TXU Energy.

view posts
Follow

Recent Blog Posts

Thu, 02/16/2012 - 4:52pm

The process of prescribing, dispensing and using 111
medications leaves little room for medical errors when the health of the consumer is at stake.

The same holds true in making sure there is no room for error in “dispensing” prescription drug and medical device information on your web sites. The new FDA guidelines present the opportunity to ensure your customers can and will find readily accessible and accurate off-label information across your company and branded web properties. With the new FDA guidance for responding to unsolicited requests for off-label information, it may be time for a cross-domain audit of your web properties – an audit to simply ensure such off-label information is current and meeting FDA requirements.

Per the FDA recommendations, a firm’s contact and disclosure information, a public response should include a mechanism for providing readily accessible current FDA-required labelling, if any, for the product (e.g., FDA-approved package insert and, if the response is for a consumer, FDA-approved patient labelling or, for new animal drugs, FDA-approved client information sheet.

Thu, 06/02/2011 - 5:16pm

59 Pharma marketers have become quite accustomed to rules, limitations and delays. Adding to this complexity and quandary is the further delay of the FDA social media guidelines. In fact, according to a recent post on John Mack’s Pharma Marketing Blog, it appears that the FDA has dropped social media from its 2011 Guidance Agenda.  But wait not for those guidelines! Successful social media in the pharma and healthcare space simply requires more careful planning with a dose of persistence on initiatives you should be doing already. And if you’re not already doing it, start today!

Other Contributors

Nancy Hicks
Senior Vice President, Associate Director, North America Healthcare Practice, Ketchum Washington DC
Nancy Hicks is head of Ketchum's North America Healthcare Practice. She serves as senior counsel to healthcare clients relying on her over 25 years of experience in healthcare communications. She is... more
Gemma Berman
Senior Account Manager, Ketchum Pleon, London
Gemma began her career in ethical healthcare Public Relations in 2006 and since then has worked on a range of UK and global communications programmes in therapeutic areas including oncology, pain,... more
Jeff Levine
Guest Contributor, Health E Minds
Jeff Levine is an award-winning journalist and broadcaster with more than 25 years of experience. For WebMD, Jeff Levine served as the Washington bureau chief. His duties included keeping an eye on... more